FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Trevi Therapeutics in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.49) for the year, down from their previous estimate of ($0.48). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.48) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the company earned ($0.08) earnings per share.

TRVI has been the subject of several other research reports. HC Wainwright upped their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th. B. Riley restated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, D. Boral Capital restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI opened at $3.99 on Thursday. Trevi Therapeutics has a 52-week low of $1.31 and a 52-week high of $4.68. The firm has a market capitalization of $306.71 million, a price-to-earnings ratio of -9.07 and a beta of 0.87. The stock has a 50 day moving average price of $3.54 and a 200 day moving average price of $3.20.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in Trevi Therapeutics by 14.5% during the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after acquiring an additional 3,387 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares in the last quarter. Barclays PLC boosted its holdings in shares of Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after purchasing an additional 53,051 shares during the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.